{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011962","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2025-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.046846+00:00","generated_at":"2026-05-20T18:15:31.671155+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem signs exclusive SOLOSEC license for UAE, Kuwait, Saudi Arabia and other Middle East countries","bullets":["Exclusive 5-year license to develop, market, and sell SOLOSEC in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.","Pharma 1 targets mid-2025 regulatory submission in UAE; must file within 3 months of agreement.","Consideration includes upfront payment, regulatory milestones, and sales-based milestones; supply at cost-plus.","SOLOSEC is FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.","Expands existing Evofem-Pharma 1 partnership beyond PHEXXI to SOLOSEC."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011962","json":"https://secwatch.observer/filing/0001641172-25-011962.json","markdown":"https://secwatch.observer/filing/0001641172-25-011962.md","text":"https://secwatch.observer/filing/0001641172-25-011962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225011962/0001641172-25-011962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225011962/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T18:15:31.671155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}